# TOFACITINIB vs TOFACITINIB WITH MESALAMINE IN ULCERATIVE COLITIS

> **NCT06625450** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Post Graduate Institute of Medical Education and Research, Chandigarh** · enrollment: 75 (estimated)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Tofacitinib
- **DRUG:** Tofacitinib plus mesalamine

## Key facts

- **NCT ID:** NCT06625450
- **Lead sponsor:** Post Graduate Institute of Medical Education and Research, Chandigarh
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10
- **Primary completion:** 2025-12
- **Final completion:** 2026-01
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2024-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06625450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06625450, "TOFACITINIB vs TOFACITINIB WITH MESALAMINE IN ULCERATIVE COLITIS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06625450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*